Pre-Conference Workshop Day
Pre-Conference Workshop Day | Tuesday, December 10, 2024
08:30am Registration & Morning Coffee
Workshop A
9:00 am Mastering the Complement System: Strategic Targeting & Preclinical Breakthroughs for Next-Generation Complement Inhibitors
Synopsis
Provides an in-depth exploration of the complement system and its therapeutic targeting for diseases. Gain comprehensive insights into the complexities of complement pathways, the strategic selection of inhibition targets, and the essential steps in preclinical development to:
- Delve into the intricacies of the complement system, with a focus on identifying critical nodes and pathways (classical, lectin, and alternative) for potential therapeutic intervention
- Understand the underlying mechanisms driving complement activation and regulation, and learn to pinpoint specific proteins or pathways that are most promising for therapeutic targeting
11:30 am Lunch Break & Networking
Workshop B
12:30 pm From Bench to Bedside: Streamlining Preclinical Strategies for Effective Complement Drug Development Across Disease Indications
Synopsis
A comprehensive guide to improving the efficacy measurement and translational success of complement inhibitors. Explore cutting-edge methodologies and best practices in preclinical research to bridge the gap between laboratory findings and clinical application.
- Conduct detailed dose-response studies to determine the optimal dosing regimen that maximizes efficacy while minimizing toxicity
- Perform extensive safety and toxicology studies in multiple animal species to identify potential side effects and establish a safety profile
- Examine the latest animal models to better mimic human responses
3:00 pm Afternoon Break & Networking
Workshop C
3:30 pm Navigating Clinical Trials: Overcoming Challenges in Complement Drug Development for Breakthrough Success
Synopsis
Delving into the strategic expansion of indications for complement inhibitors beyond their initial targets. Explore the processes and considerations involved in identifying new therapeutic areas, conducting late-stage translational
research, and managing clinical development to bring these therapies from rare disease to indications like dry AMD.
- Design trials that include both traditional and innovative endpoints, such as patient-reported outcomes or biomarkers, and ensure robust safety monitoring to mitigate risks
- Utilize global recruitment strategies and patient registries and engaging with patient advocacy groups to overcome these challenges
- Re-evaluate the importance of real-world evidence and post-marketing surveillance in supporting expanded use
6:00 pm End of Pre-Conference Workshop Day
